SAT0370 EVALUATIONS OF EXERTION DYSPNEA IN PATIENTS WITH CONNECTIVE TISSUE DISEASE (CTD) BY CPET (CARDIOPULMONARY EXERCISE TESTING) FOR EARLY DETECTING ASSOCIATED PULMONARY HYPERTENSION (APAH)
Y. Nobuhara, Y. Kamei, Y. Fujikawa, T. Nakazawa. Rheumatology, Osaka saiseikai nakatsu hospital, Osaka, Japan Background: Patients with CTD often complain of exertion dyspnea, due to lung diseases, heart diseases, musculoskeletal disorders and/or APAH. Although imaging and physiological tests could reveal pathophysiology, some of them remain unknown. Especially APAH is rarely diagnosed in WHO functional class I or II, because pulmonary vasculopathy (PV) cannot be detected until two-thirds of pulmonary blood vessels deteriorated, 1 with cardiac ultrasonography (UCG) or right heart catheterization (RHC) at rest. Pathophysiological considerations suggest that the haemodynamic/metabolic impairment in APAH may be observed during exercise before the disease becomes evident at rest. [2] [3] We evaluated exertion dyspnea of unknown to find out early APAH with CPET. Objectives: We performed CPET in patients who complained of exertion dyspnea and tried to detect early PV. Methods: From June 13th in 2015 to October 28th in 2016, we performed CPET and evaluate their clinical state in 28 patients, 17-80 years 2 males/26 females, 5 mixed connective tissue disease (MCTD), 15 SSc, 3 SLE, 2 Sjögren's syndrome, 3 dermatomyositis. They underwent UCG, pulmonary function testing (PFT), 6-minutes walk test, and nailfold capillaroscopy by Cutolo's method. Results: Twenty cases presented decreased peak VO2. VE/VCO 2 ratio, which represent increased ventilation-perfusion mismatch, elevated in 12 cases. 8 cases, with decreased peak VO2 but normal VE/VCO 2, were regarded that muscle weakness mainly induced exertion dyspnea, and advised exercise. Twelve cases with decreased peak VO2 and elevated VE/VCO 2 were estimated to have APAH or/and interstitial lung disease (ILD). Seven of them underwent RHC and 1 case diagnosed as definite APAH, and another 1 case as post capillary PH. A 34 years MCTD woman without ILD showed an active capillaroscopic pattern, her peak VO2 decreased (13.9ml/kg/min.) and nadir VE/VCO 2 elevated (39). Although her mean PAP was normal, we suspected she had early PV and administered PDE5 inhibitor to her and her dyspnea had gone soon and CPET parameters improved. CPET was also useful for early detections of therapeutic gains in APAH. A SSc woman, diagnosed as APAH by RHC, was performed CPET only 9 days after administration of PDE5 inhibitor. Her peak VO2 elavated (13.3 to 15.4 ml/kg/min.) and nadir VE/VCO 2 decreased (43.4 to 38.9) promptly. Thirteen patients showed an early capillaroscopic pattern, 7 an active pattern and 3 a late pattern. Background: Idiopathic inflammatory myopathies are chronic, heterogeneous systemic autoimmune diseases with symmetrical proximal muscle weakness. During the disease course, osteoporosis and bone fractures are more common compared to the healthy population, which can be explained by the chronic inflammation, immobilization, spontaneous falls and steroid treatment, and affect crucially the patients' quality of life. Recently, a WHO fracture risk calculation tool, FRAX score is available, to measure the 10-year probability of osteoporotic fractures. It takes into account relevant clinical risk factors, such as rheumatoid arthritis, however myositis does not exist among the risk factors. Objectives: Estimation the effect of myositis and myositis related bone mineral densities on bone fracture risk calculated by FRAX tool. Methods: FRAX score was determined in 71 patients with idiopathic inflammatory myopathies and results were compared with the data from 50 age, sex and BMI matched patients with rheumatoid arthritis. Moreover, osteoporosis related biomarkers, disease related fractures and bone mineral densities were determined using DXA examinations. Statistical analysis was performed with IBM SPSS 20.0 software. Results: There were no significant differences between the demographical data, biomarkers (Ca, Vitamin D, parathormone level) of the two groups. Disease duration and cumulative steroid dose were higher in the myositis group. Results of the FRAX score without BMD were significantly lower in the patients with myositis, in both fracture risk: major osteoporotic (8,61±6,36%, vs. 15,59±12,66%; p: 0,002) and femur neck (2,66±3,24%, vs. 6,34±9,018; p: 0.003). T score results of the DXA examination were not significantly different between the two populations (Lumbar1-4: -0,9±1,43 vs.-0,829±1,38; p:0,829; Femoral neck: -1,4±1,08 vs. -1,02±1,08; p: 0,93), but the presence of osteopenia (60% vs. 39,5%) and osteoporosis (13,5% vs. 7%) were more frequent in the myositis group (p: 0,045). Disease related fracture was associated with disease duration in the myositis group and with antibody (RF, ACPA) presence in the RA group. FRAX score with BMD results showed no significant differences between the two populations (Major osteoporotic: 9,44±6,72 vs. 13,25±9,43; p: 0,053; Hip: 2,77±3,01 vs. 3,57±5,08; p: 0,811). Conclusions: As far as we know, this is the first study which examine the fracture risk using FRAX score in patients with idiopathic inflammatory myopathies. According to our data, we can conclude that existence of myositis might indicate similar, independent risk factor in fracture probability, like rheumatoid arthritis. Evaluation of fracture risk should be done with DXA result in patients with IIM, otherwise risk could be underestimated. An exact value of the "myositis related risk" could be determined by a 10-year prospective study. Background: Anti-nuclear antibodies (ANA), which are present in approximately 90% of systemic sclerosis (SSc) patient's sera, play an important role in establishing the diagnosis and predicting prognosis of SSc. Recently, a novel autoantibody has been described in SSc patients targeting Cytoskeleton-Like Bicaudal D Protein Homolog 2 (BICD2). Objectives: The aim of this study was to assess the prevalence and titers of anti-BICD2 antibodies in SSc and controls and to study the clinical associations of this new antibody. Methods: A total of 502 samples from SSc patients enrolled in the Canadian Scleroderma Research Group (CSRG) cohort were included in this study. Clinical associations were assessed either as anti-BICD2 antibody positivity with and without other autoantibodies present using 451 SSc patients with complete dataset. Autoantibodies to several scleroderma-related autoantibodies were detected using commercial or research use only kits (Inova Diagnostics, San Diego, USA). P-values below 0.05 were considered significant. Results: The sensitivity and specificity of anti-BICD2 antibodies were determined as 22.1% and 99.0%, respectively. Receiver operating characteristic (ROC) analysis showed an area under the curve of 0.79 (95% CI 0.75-0.84). The likelihood (LR) and odds ratios (OR) were 17.7 (LR+), 0.8 (LR-) and 20.4 (OR). The prevalence of these autoantibodies was equally distributed between limited and diffuse form of SSc (22.8% and 24.0%). When SSc patients without the classification criteria markers anti-Scl-70, anti-Centromere and anti-RNA Pol III (n=184) were compared with controls, similar performance was obtained as seen in the entire cohort. Results are summarized in table 1 below. Background: Treatment with tocilizumab (TCZ) in early systemic sclerosis (SSc; FaSScinate trial) resulted in consistent, but not statistically significant, improvements in skin sclerosis (mRSS) at wks 24 and 48 1 . The CRISS index has been proposed as a composite index for trials in SSc 2 . CRISS is a 2-step process that assigns a probability of improvement for each subject ranging from 0.0 [no improvement] to 1.0 [marked improvement].
Step 1 assesses clinically meaningful decline in cardio-pulmonary-renal involvement and assigns a probability of 0.0. For remaining subjects, 5 variables are used to calculate probability of improvement. These are: FVC%, mRSS, patient (PT GA) and physician globals (MD GA), and HAQ-DI. Objectives: To assess the performance of CRISS index in the FaSScinate trial. Methods: In FaSScinate, pts ≥18 y with active SSc were randomized 1:1 to TCZ or placebo (PLA) for 48 wks.
Step 1 CRISS was captured using review of serious adverse event data. Non-parametric Wilcoxon test was used to assess significant differences between the CRISS scores in both arms. Analyses were carried out for subject who had complete data at baseline and 24 weeks and at baseline and 48 weeks. Results: 87 pts (43 TCZ, 44 PBO) were enrolled. Baseline characteristics were similar between arms. 4 subjects in the PBO group and none in TCZ met the pre-defined definition of worsening in Step 1 and were given a score of 0.0. For remaining subjects, we calculated probability score for each subject. Using CRISS as a continuous measure, the median score was statistically significant and favored TCZ compared to PBO at wks 24 and 48 (p=0.04 and 0.01; Table) . *Using Wilcoxon test as CRISS data is not normally distributed. **There are 4 subjects in the PBO who met step 1 and were given a score of 0.0.
